25B-NB

25B-NB, also known as N-benzyl-4-bromo-2,5-dimethoxyphenethylamine, is a recreational designer drug from the 25-NB subgroup of the substituted phenethylamine family, with psychedelic effects. It has a binding affinity of 16 nM at the serotonin receptor 5-HT_2A and 90 nM at 5-HT_2C and reportedly has a potency in between that of 2C-B and 25B-NBOMe. 25B-NB was first synthesized and described by Richard Glennon and colleagues in 1994. It was the first drug of the 25-NB family to be developed. Subsequently, modification of 25B-NB led to the development of the more well-known 25-NB family drugs such as 25I-NBOMe. 25B-NB is a controlled substance in Canada under phenethylamine blanket-ban language.